Detection of a latent soluble form of membrane type 1 matrix metalloprotease bound with tissue inhibitor of matrix metalloproteinases-2 in periprosthetic tissues and fluids from loose arthroplasty endoprostheses

FEBS Journal

Volumn 280, Issue 24, 2013, Pages 6541-6555

  Niarakis, Anna ^a   Giannopoulou, Eleftheria ^a   Ravazoula, Panagiota ^b   Panagiotopoulos, Elias ^a   Zarkadis, Ioannis K ^a   Aletras, Alexios J ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

loose arthroplasty endoprostheses; periprosthetic tissues; soluble membrane type 1 matrix metalloproteinase; tissue inhibitor of matrix metalloproteinases 2

Indexed keywords

ENZYME PRECURSOR; MATRIX METALLOPROTEINASE 14; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

AMINO TERMINAL SEQUENCE; ARTICLE; CANCER CELL; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE; CONTROLLED STUDY; ENDOPROSTHESIS; ENDOPROSTHESIS LOOSENING; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; FIBROBLAST; GIANT CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; LUNG DISEASE; NORTHERN BLOTTING; NOSE POLYP; PERIPROSTHETIC TISSUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; WESTERN BLOTTING;

LOOSE ARTHROPLASTY ENDOPROSTHESES; PERIPROSTHETIC TISSUES; SOLUBLE MEMBRANE TYPE 1 MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF MATRIX METALLOPROTEINASES-2;

ARTHRITIS, RHEUMATOID; ARTHROPLASTY; BLOTTING, NORTHERN; BLOTTING, WESTERN; CHROMATOGRAPHY, AFFINITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLASTS; GIANT CELLS; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; KNEE PROSTHESIS; LUNG DISEASES; MATRIX METALLOPROTEINASE 14; NASAL POLYPS; NOSE DISEASES; OSTEOARTHRITIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SYNOVIAL FLUID; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 84889661166     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12555     Document Type: Article

References (63)

1. Sundfeldt M, Carlsson LV, Johansson CB, Thomsen P, &, Gretzer C, (2006) Aseptic loosening, not only a question of wear: a review of different theories. Acta Orthop 77, 177-197.
2. Abu-Amer Y, Darwech I, &, Clohisy JC, (2007) Aseptic loosening of total joint replacements: mechanisms underlying osteolysis and potential therapies. Arthritis Res Ther 9 (Suppl. 1), S6.
3. Takagi M, (1996) Neutral proteinases and their inhibitors in the loosening of total hip prostheses. Acta Orthop Scand Suppl 271, 3-29.
4. Takei I, Takagi M, Santavirta S, Ida H, Hamasaki M, Ishii M, Fukushima S, Ogino T, &, Konttinen YT, (1999) Matrix metalloproteinases and tissue inhibitors of metalloproteinases in joint fluid of the patients with loose artificial hip joints. J Biomed Mater Res 45, 175-183.
5. Syggelos SA, Eleftheriou SC, Giannopoulou E, Panagiotopoulos E, &, Aletras AJ, (2001) Gelatinolytic and collagenolytic activity in periprosthetic tissues from loose hip endoprostheses. J Rheumatol 28, 1319-1329.
6. Nagase H, Visse R, &, Murphy G, (2006) Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69, 562-573.
7. Gialeli C, Theocharis AD, &, Karamanos NK, (2011) Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 278, 16-27.
8. Knäuper V, &, Murphy G, (1998) Membrane type-matrix metalloproteinases and cell surface-assiciated activation cascade for matrix metalloproteinases. In Matrix Metalloproteinases (, Parks WC, &, Mecham RP, eds.), pp 199-218. Academic Press, Harcourt Brace & Company, Publishers, San Diego, London, Boston, New York, Sydney, Toronto.
9. Polette M, &, Birembaut P, (1998) Membrane-type metalloproteinases in tumor invasion. Int J Biochem Cell Biol 30, 1195-1202.
10. Hernandez-Barrantes S, Bernardo M, Toth M, &, Fridman R, (2002) Regulation of membrane type-matrix metalloproteinases. Semin Cancer Biol 12, 131-138.
11. Sounni NE, &, Noel A, (2005) Membrane type-matrix metalloproteinases and tumor progression. Biochimie 87, 329-342.
12. Yana I, &, Weiss SJ, (2000) Regulation of membrane type-1 matrix metalloproteinase activation by proprotein convertases. Mol Biol Cell 11, 2387-2401.
13. Butler GS, Butler MJ, Atkinson SJ, Will H, Tamura T, van Westrum SS, Crabbe T, Clements J, d'Ortho MP, &, Murphy G, (1998) The TIMP2 membrane type 1 metalloproteinase 'receptor' regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem 273, 871-880.
14. Morgunova E, Tuuttila A, Bergmann U, &, Tryggvason K, (2002) Structural insight into the complex formation of latent matrix metalloproteinase 2 with tissue inhibitor of metalloproteinase 2. Proc Natl Acad Sci USA 99, 7414-7419.
15. Hernandez-Barrantes S, Toth M, Bernardo MM, Yurkova M, Gervasi DC, Raz Y, Sang QA, &, Fridman R, (2000) Binding of active (57 kDa) membrane type 1-matrix metalloproteinase (MT1-MMP) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP processing and proMMP-2 activation. J Biol Chem 275, 12080-12089.
16. Bernardo MM, &, Fridman R, (2003) TIMP-2 (tissue inhibitor of metalloproteinase-2) regulates MMP-2 (matrix metalloproteinase-2) activity in the extracellular environment after proMMP-2 activation by MT1 (membrane type 1)-MMP. Biochem J 374, 739-745.
17. Toth M, Chvyrkova I, Bernardo MM, Hernandez-Barrantes S, &, Fridman R, (2003) ProMMP-9 activation by the MT1-MMP/MMP-2 axis and MMP-3: role of TIMP-2 and plasma membranes. Biochem Biophys Res Commun 308, 386-395.
18. Ohuchi E, Imai K, Fujii Y, Sato H, Seiki M, &, Okada Y, (1997) Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem 272, 2446-2451.
19. Barbolina MV, &, Stack MS, (2008) Membrane type 1-matrix metalloproteinase: substrate diversity in pericellular proteolysis. Semin Cell Dev Biol 19, 24-33.
20. Will H, Atkinson SJ, Butler GS, Smith B, &, Murphy G, (1996) The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3. J Biol Chem 271, 17119-17123.
21. Kazes I, Delarue F, Hagège J, Bouzhir-Sima L, Rondeau E, Sraer JD, &, Nguyen G, (1998) Soluble latent membrane-type 1 matrix metalloprotease secreted by human mesangial cells is activated by urokinase. Kidney Int 54, 1976-1984.
22. Li H, Bauzon DE, Xu X, Tschesche H, Cao J, &, Sang QA, (1998) Immunological characterization of cell-surface and soluble forms of membrane type 1 matrix metalloproteinase in human breast cancer cells and in fibroblasts. Mol Carcinog 22, 84-94.
23. Lohi J, Lehti K, Westermarck J, Kähäri VM, &, Keski-Oja J, (1996) Regulation of membrane-type matrix metalloproteinase-1 expression by growth factors and phorbol 12-myristate 13-acetate. Eur J Biochem 239, 239-247.
24. Okumura Y, Sato H, Seiki M, &, Kido H, (1997) Proteolytic activation of the precursor of membrane type 1 matrix metalloproteinase by human plasmin: a possible cell surface activator. FEBS Lett 402, 181-184.
25. Toth M, Hernandez-Barrantes S, Osenkowski P, Bernardo MM, Gervasi DC, Shimura Y, Meroueh O, Kotra LP, Galvez BG, Arroyo AG, et al,. (2002) Complex pattern of membrane type-1 matrix metalloproteinase shedding. Regulation by autocatalytic cell surface inactivation of active enzyme. J Biol Chem 277, 26340-26350.
26. Toth M, Osenkowski P, Hesek D, Brown S, Meroueh S, Sakr W, Mobashery S, &, Fridman R, (2005) Cleavage at the stem region releases an active ectodomain of the membrane type 1 matrix metalloproteinase. Biochem J 387, 497-506.
27. Harayama T, Ohuchi E, Aoki T, Sato H, Seiki M, &, Okada Y, (1999) Shedding of membrane type 1 matrix metalloproteinase in a human breast carcinoma cell line. Jpn J Cancer Res 90, 942-950.
28. Zucker S, Drews M, Conner C, Foda HD, DeClerck YA, Langley KE, Bahou WF, Docherty AJ, &, Cao J, (1998) Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP). J Biol Chem 273, 1216-1222.
29. Galvez BG, Matias-Roman S, Albar JP, Sanchez-Madrid F, &, Arroyo AG, (2001) Membrane type 1-matrix metalloproteinase is activated during migration of human endothelial cells and modulates endothelial motility and matrix remodeling. J Biol Chem 276, 37491-37500.
30. Maisi P, Prikk K, Sepper R, Pirila E, Salo T, Hietanen J, &, Sorsa T, (2002) Soluble membrane-type 1 matrix metalloproteinase (MT1-MMP) and gelatinase A (MMP-2) in induced sputum and bronchoalveolar lavage fluid of human bronchial asthma and bronchiectasis. APMIS 110, 771-782.
31. Itoh Y, Binner S, &, Nagase H, (1995) Steps involved in activation of the complex of pro-matrix metalloproteinase 2 (progelatinase A) and tissue inhibitor of metalloproteinases (TIMP)-2 by 4-aminophenylmercuric acetate. Biochem J 308, 645-651.
32. Migita K, Eguchi K, Kawabe Y, Ichinose Y, Tsukada T, Aoyagi T, Nakamura H, &, Nagataki S, (1996) TNF-α-mediated expression of membrane-type matrix metalloproteinase in rheumatoid synovial fibroblasts. Immunology 89, 553-557.
33. Büttner FH, Chubinskaya S, Margerie D, Huch K, Flechtenmacher J, Cole AA, &, Bartnik E, (1997) Expression of membrane type 1 matrix metalloproteinase in human articular cartilage. Arthritis Rheum 40, 704-709.
34. Imai K, Ohta S, Matsumoto T, Fujimoto N, Sato H, Seiki M, &, Okada Y, (1997) Expression of membrane-type 1 matrix metalloproteinase and activation of progelatinase A in human osteoarthritic cartilage. Am J Pathol 151, 245-256.
35. Yamanaka H, Makino K, Takizawa M, Nakamura H, Fujimoto N, Moriya H, Nemori R, Sato H, Seiki M, &, Okada Y, (2000) Expression of tissue localization of mambrane-types 1, 2 and 3 matrix metalloproteinases in rheumatoid synovium. Lab Invest 80, 677-687.
36. Honda S, Migita K, Hirai Y, Origuchi T, Yamasaki S, Kamachi M, Shibatomi K, Fukuda T, Kita M, Hida A, et al,. (2001) Expression of membrane-type 1 matrix metalloproteinase in rheumatoid synovial cells. Clin Exp Immunol 126, 131-136.
37. Nakada M, Nakamura H, Ikeda E, Fujimoto N, Yamashita J, Sato H, Seiki M, &, Okada Y, (1999) Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors. Am J Pathol 154, 417-428.
38. Nakamura H, Ueno H, Yamashita K, Shimada T, Yamamoto E, Noguchi M, Fujimoto N, Sato H, Seiki M, &, Okada Y, (1999) Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas. Cancer Res 59, 467-473.
39. Tsunezuka Y, Kinoh H, Takino T, Watanabe Y, &, Okada Y, (1996) Expression of membrane-type matrix metalloproteinase 1 (MT1-MMP) in tumor cells enhances pulmonary metastasis in an experimental metastasis assay. Cancer Res 56, 5678-5683.
40. Ueno H, Nakamura H, Inoue M, Imai K, Noguchi M, Sato H, Seiki M, &, Okada Y, (1997) Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res 57, 2055-2060.
41. Simiantonaki N, Jayasinghe C, &, Kirkpatrick CJ, (2002) Differential endothelial CAM-expression after stimulation with supernatants of LPS- and cytokine-stimulated HT-29 and ST-ML-12 tumor cells growing as monolayer cultures and multicellular spheroids. Anticancer Res 22, 2641-2649.
42. Yu M, Sato H, Seiki M, &, Thompson EW, (1995) Complex regulation of membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation by concanavalin A in MDA-MB-231 human breast cancel cells. Cancer Res 55, 3272-3277.
43. Sato T, del Carmen Ovejero M, Hou P, Heegaard AM, Kumegawa M, Foged NT, &, Delaissé JM, (1997) Identification of the membrane-type matrix metalloproteinase MT1-MMP in osteoclasts. J Cell Sci 110, 589-596.
44. Nguyen M, Arkell J, &, Jackson CJ, (2000) Three-dimensional collagen matrices induce delayed but sustained activation of gelatinase A in human endothelial cells via MT1-MMP. Int J Biochem Cell Biol 32, 621-631.
45. Takino T, Sato H, Yamamoto E, &, Seiki M, (1995) Cloning of a human gene potentially encoding a novel matrix metalloproteinase having a C-terminal transmembrane domain. Gene 155, 293-298.
46. Imai K, Ohuchi E, Aoki T, Nomura H, Fujii Y, Sato H, Seiki M, &, Okada Y, (1996) Membrane-type matrix metalloproteinase 1 is a gelatinolytic enzyme and is secreted in a complex with tissue inhibitor of metalloproteinases 2. Cancer Res 56, 2707-2710.
47. Okada A, Bellocq J-P, Rouyer N, Chenard M-P, Rio M-C, Chambon P, &, Basset P, (1995) Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci USA 92, 2730-2734.
48. Lehti K, Lohi J, Valtanen H, &, Keski-Oja J, (1998) Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface. Biochem J 334, 345-353.
49. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, &, Goldberg GI, (1995) Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 270, 5331-5338.
50. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, &, Seiki M, (1994) A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370, 61-65.
51. Cao J, Drews M, Lee HM, Conner C, Bahou WF, &, Zucker S, (1998) The propeptide domain of membrane type 1 matrix metalloproteinase is required for binding of tissue inhibitor of metalloproteinases and for activa-tion of pro-gelatinase A. J Biol Chem 273, 34745-34752.
52. Cao J, Hymowitz M, Conner C, Bahou WF, &, Zucker S, (2000) The propeptide domain of membrane type 1-matrix metalloproteinase acts as an intramolecular chaperone when expressed in trans with the mature sequence in COS-1 cells. J Biol Chem 275, 29648-29653.
53. Pavlaki M, Cao J, Hymowitz H, Chen WT, Bahou W, &, Zucker SA, (2002) Conserved sequence within the propeptide domain of membrane type 1 matrix metalloproteinase is critical for function as an intramolecular chaperone. J Biol Chem 277, 2740-2749.
54. Ogata Y, Itoh Y, &, Nagase H, (1995) Steps involved in activation of the pro-matrix metalloproteinase 9 (progelatinase B)-tissue inhibitor of metalloproteinases-1 complex by 4-aminophenylmercuric acetate and proteinases. J Biol Chem 270, 18506-18511.
55. Goldberg GI, Strongin A, Collier IE, Genrich T, &, Marmer BL, (1992) Interaction of 92 kDa type IV collagenase with the tissue inhibitor of metallopro-teinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem 267, 4583-4591.
56. Pawliczak R, Lewandowska-Polak A, &, Kowalski ML, (2005) Pathogenesis of nasal polyps: an update. Curr Allergy Asthm R5, 463-471.
57. Firestein GS, Yeo M, &, Zvaifler NJ, (1995) Apoptosis in rheumatoid arthritis synovium. J Clin Invest 96, 1631-1638.
58. Pavlaki M, Giannopoulou E, Niarakis A, Ravazoula P, &, Aletras AJ, (2009) Walker 256 cancer cells secrete tissue inhibitor of metalloproteinase- free metalloproteinase-9. Mol Cell Biochem 328, 189-199.
59. Sato T, Ito A, &, Mori Y, (1990) Interleukin 6 enhances the production of tissue inhibitor of metalloproteinases (TIMP) but not that of matrix metalloproteinases by human fibroblasts. Biochem Biophys Res Commun 170, 824-829.
60. Laemmli UK, (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685.
61. Moore BA, Aznavoorian S, Engler JA, &, Windsor LJ, (2000) Induction of collagenase-3 (MMP-13) in rheumatoid arthritis synovial fibroblasts. Biochim Biophys Acta 1502, 307-318.
62. Hsu SM, Raine L, &, Fanger H, (1981) Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29, 577-580.
63. Bradford MM, (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72, 248-254.